Adjuvant Therapy for Melanoma: High-Dose Interferon
Author Information
Author(s): PG de Takats, MV Williams, R Hawkins
Primary Institution: Oncology Centre, Addenbrooke's NHS Trust
Hypothesis
Does high-dose interferon alpha 2b improve survival in patients at high risk of recurrence after surgery for melanoma?
Conclusion
High-dose interferon alpha 2b therapy shows a significant survival benefit in patients with high-risk melanoma.
Supporting Evidence
- High-dose interferon alpha 2b therapy showed significant prolongation of relapse-free and overall survival.
- The study is the first to demonstrate a durable statistically significant survival benefit from any medical therapy after surgery for melanoma.
- Over 50% of patients with thick primary tumors or regional lymph node involvement relapse or die within 2 years of surgery.
Takeaway
This study found that giving high-dose interferon can help people with melanoma live longer after surgery.
Methodology
Randomized controlled trial comparing high-dose interferon alpha 2b to observation in melanoma patients after surgery.
Potential Biases
Potential bias due to the one-tailed test assumption that treatment would be superior.
Limitations
The study's findings may not be generalizable due to the specific patient population and treatment protocols used.
Participant Demographics
Patients with thick primary or regional lymph node-positive malignant melanoma, median age below 50.
Statistical Information
P-Value
0.0023 for relapse-free survival, 0.0237 for overall survival
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website